(Q37981760)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309606%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Ranibizumab for age-related macular degeneration (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309606%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309606%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Dilsher S Dhoot

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309606%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

language of work or name

English

0 references

publication date

6 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309606%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309606%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309606%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309606%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

371-381

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309606%20AND%20SRC:MED&resulttype=core&format=json

Prevalence of age-related macular degeneration in the United States

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Ranibizumab for the treatment of neovascular AMD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Current concepts in the pathogenesis of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Reduced foveolar choroidal blood flow in eyes with increasing AMD severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Increased expression of angiogenic growth factors in age-related maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Vascular endothelial growth factor biology: clinical implications for ocular treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

neovascular age-related macular degeneration: Natural History and Treatment Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Emerging therapies for the treatment of neovascular age related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Human retinal molecular weight exclusion limit and estimate of species variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

"Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Alterations in serum fatty acid concentrations and desaturase activities in Bietti crystalline dystrophy unaffected by CYP4V2 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.660523

10.1517/14712598.2012.660523

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22309606%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference